Full-Time

Centralized Clinical Trial Manager

Updated on 7/21/2026

Icon

Icon

10,001+ employees

Global drug and device development services

No salary listed

Chennai, Tamil Nadu, India + 1 more

More locations: Bengaluru, Karnataka, India

Hybrid

Hybrid role with some on-site days; work from home options may be available in India.

Category
Biology & Biotech (1)

Get referred to Icon

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in life sciences, healthcare, or a related field (advanced degree preferred).
  • Minimum 8-10 years of Clinical Research experience with at least 5 years of on-site monitoring experience.
  • Experience in On-Site Monitoring and Clinical Trial Management, with a solid understanding of on-site monitoring approaches.
  • Strong analytical skills with proficiency in clinical trial data review and interpretation.
  • Excellent organizational and project management skills, with the ability to manage multiple studies and meet deadlines.
  • Effective communication and interpersonal skills, with the ability to collaborate across diverse teams and functions.
Responsibilities
  • To effectively review visit reports as per Protocol and ICON and Sponsor SOPs and to ensure the quality of reports are of the highest standards, errors are minimized and that issues are escalated as appropriate
  • To follow up on action items and protocol deviations and to be a liaison between CRA, CTM and PM for timely resolution of issues.
  • To act as an extension of the CTM/CTM team for the specific purpose of visit report review and approval.
  • To observe and escalate safety trends in patients as identified in visit report
  • As a Manager, to recognize the importance of and create a culture of process improvement with a focus on streamlining processes adding value to the business and meeting client needs.
  • Effectively review and approve visit reports as per annotated report, protocol, ICON and/or Sponsor SOPs and ensure errors are minimized, reports are consistent across visits and sites and adhere to the highest standards of quality. Ensure turnaround time of the visit reports per contract, ICON and or Sponsor SOPs
  • Regular oversight of OMR, ICO trial (and where required Sponsor CTMS and vendor systems) to ensure key metrics, e.g. MVR and FUL timelines, Action Items and other quality metrics are being met and followed-up as necessary
  • Ensure open action items and protocol deviations are escalated and followed up for timely resolution as per contract or corporate standards.
  • Attend project meetings and actively provide suggestions for improvement of quality of reports, provide feedback for timely and appropriate resolution of action items and report trends
  • Liaise with CTM to communicate any trends, outstanding issues, safety concerns or any other activity or lack thereof which may jeopardise the clinical trial delivery or patient safety.
  • Ensure all necessary trainings, required to improve job performance managing people and project or process related issues which are necessary to perform successfully in a service oriented environment.
  • Thorough knowledge of ICH GCP and relevant regulations for the conduct of clinical trials.
  • Fluent in written and spoken English.
  • Computer literate.
  • Ability and willingness to travel if required
  • Extensive use of telephone expected continuous improvement in trial processes.
Desired Qualifications
  • Advanced degree in life sciences, healthcare, or a related field (preferred).
  • Any specific therapeutic area expertise or regulatory experience mentioned elsewhere in the posting is not explicitly listed as desirable other than ICH GCP knowledge.

Provides consulting, development, and commercialization services for drugs and medical devices through a global network to help clients accelerate development and bring products to market. A global team of experts in 53 countries offers end-to-end support across strategy, development, regulatory, manufacturing, and market access to reduce time to market, lower costs, and improve quality. The company differentiates itself with its large global presence, clear focus on speed and cost, and extensive experience across therapeutic areas. Its goal is to help clients accelerate the development of life-saving drugs and devices by delivering high-quality information, solutions, and performance.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Get referred to Icon

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Gross bookings rose 22% YoY to $3.3B in Q1 2026, signaling strong underlying demand and recovery momentum.
  • Board refresh added financial experts Kevin Egan and Jeff Elliott, while $750M buyback aims to rebuild investor confidence.
  • Analysts project organic revenue growth return in 2027 as ICON recovers from 2023–2024 revenue overstatement issues.

What critics are saying

  • Persistent investor distrust and capital access erosion due to unresolved accounting scandal fallout over 6–12 months with high impact.
  • Loss of Big Pharma contracts from perceived control weaknesses and reputational damage over 9–15 months with high impact.
  • Margin compression and revenue decline from canceled trials and reduced win rates post-scandal over 6–12 months with high impact.

What makes Icon unique

  • ICON scales Orbis agentic AI via Microsoft 365 Copilot deployment to digitize protocols and detect risks in real time.
  • ICON's connected site network with Advarra integrates CTMS and eSource systems to reduce administrative burden and accelerate startup.
  • ICON expands early-phase oncology capabilities with new San Antonio facility and satellite clinics in Houston and Kansas.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

31%

1 year growth

31%

2 year growth

31%
Resonate Group
Mar 24th, 2026
Icon, Advarra partnership aims to optimize trials, expand access.

Icon, Advarra partnership aims to optimize trials, expand access. * March 24, 2026 Clinical research organization Icon has entered into a partnership with research technology company Advarra to launch a network of connected sites for clinical trials. Fields (*) Mark are Required

Business Wire
Mar 24th, 2026
ICON and Advarra launch connected site network to streamline clinical trials

ICON plc and Advarra have partnered to introduce a "research-ready" connected site network model for clinical trials. The partnership integrates ICON's global clinical trial solutions with Advarra's site systems, already used by over 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres. The collaboration will create a shared operating environment that reduces administrative burden, accelerates study startup and increases clinical trial participation. Advarra will provide operational intelligence through its Braid AI platform to help ICON optimise protocol design and improve site identification. The companies plan to equip emerging and research-naïve sites with Advarra's technology, enabling broader geographic diversity in clinical trials. Last year, Advarra's systems managed over $4 billion in trial invoice value and three million patient visits.

Contract Pharma
Mar 24th, 2026
ICON, Advarra partner on connected site network model.

ICON, Advarra partner on connected site network model. Partnership will integrate ICON's global clinical trial services with Advarra's site CTMSs, eISF, and eSource systems. March 24, 2026 Managing Editor, Contract Pharma ICON plc, a clinical research organization, and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new 'research-ready,' connected site network model for clinical trials. The partnership will integrate ICON's global clinical trial services with Advarra's site CTMSs, eISF, and eSource systems. This approach leverages Advarra's Study Collaboration as the connector to ICON's technology to create a shared operating environment for ICON studies that aims to reduce administrative friction, accelerate study startup, and increase clinical trial participation. Advarra will also provide ICON with operational intelligence through Study Collaboration, built on Braid, Advarra's data and AI platform that draws on operational insights from its IRB and clinical trial systems. The intelligence will help ICON further optimize protocol design, improve forecasting and study planning, and strengthen research site identification and feasibility decisions. With a clearer understanding of research site capacity, workflow realities, and historical operational patterns, the goal is to allow for studies to be planned more realistically and executed with fewer downstream adjustments. In addition, ICON and Advarra will work together to expand access to clinical trials by enabling more research sites worldwide to support today's increasingly complex study requirements. The companies plan to equip emerging and research-naïve sites, along with select sites working with ICON, with Advarra's site technology, helping standardize operations and reduce manual processes. "Research sites should not have to adapt their operations for every new study or sponsor, and ICON and Advarra are focused on meeting sites where they are, prioritising their needs and removing that burden through this partnership," said Barry Balfe, CEO of ICON plc. "By aligning ICON's workflows with the systems sites already use every day, we're advancing a more practical and scalable way to run trials that reduces administrative burden on sites." "Sites do their best work when they can stay focused on patients and study delivery, not on managing fragmented processes," said Gadi Saarony, CEO of Advarra. "By integrating ICON's technology with the Advarra systems sites already use, this partnership allows sites to work in their native systems, reducing rework, improving consistency, and streamlining workflows. For sponsors, it means trials can move forward with greater speed and confidence, helping promising therapies move through development more efficiently and reach patients sooner."

Yahoo Finance
Mar 5th, 2026
Jefferies upgrades ICON to buy as accounting probe selloff deemed overdone

Jefferies has upgraded ICON Public Limited Company to Buy from Hold, lowering its price target to $135 from $175. Analyst David Windley cited the stock's valuation as "hard to ignore", noting that whilst AI could compress labour-intensive businesses, the market may underestimate regulatory hurdles to rapid tech adoption. The upgrade follows TD Cowen's recent move to Buy from Hold with a $120 price target, describing the risk-reward as "compelling" after a 33% selloff tied to an internal accounting investigation. ICON disclosed in February that preliminary findings indicate revenue for 2023 and 2024 may have been overstated by less than 2% each year. The company withdrew its 2025 guidance and plans to release fourth-quarter results by 30th April.

PR Newswire
Feb 18th, 2026
ICON plc shares drop 40% after internal probe uncovers $160M annual revenue overstatement

ICON plc, one of the world's largest contract research organisations, is facing investigation after disclosing on 12 February that an internal accounting probe uncovered preliminary evidence of revenue overstatements by up to 2% in fiscal years 2023 and 2024. The disclosure prompted the company to delay releasing its fourth-quarter and full-year 2025 financial results. With reported annual revenue exceeding $8 billion, a 2% overstatement would represent approximately $160 million per year. Following the announcement, ICON shares declined roughly 40%, erasing billions in market capitalisation. Law firm Levi & Korsinsky is investigating the Dublin-based company, which provides outsourced drug development and clinical trial management services. During 2025, ICON repurchased $750 million of its own shares and authorised an additional $1 billion buyback programme.